The G2 phase is the period in the cell cycle between DNA replication and cell division. It typically lasts about 3 to 6 hours in human cells and serves as a final preparation and quality-control stage, giving the cell time to grow, build proteins needed for division, and repair any DNA errors before splitting into two daughter cells.
Where G2 Fits in the Cell Cycle
The cell cycle has four main phases. In G1, the cell grows and prepares to copy its DNA. In S phase, the entire genome is replicated. G2 follows S phase, and then M phase (mitosis) completes the process by physically dividing the cell in two. The “G” stands for “gap,” because early researchers saw G1 and G2 as quiet intervals between the more dramatic events of DNA synthesis and division. That label undersells what’s actually happening: G2 is one of the busiest quality-control windows in the entire cycle.
In cultured human cells, the full cycle takes roughly 21 hours on average. Cells spend about 4 hours in G1, 9 hours in S phase, 5 to 6 hours in G2, and less than an hour in mitosis. That pattern holds across several human cell types, though the exact timing varies with cell type and growth conditions.
What the Cell Does During G2
G2 is fundamentally about getting ready to divide. The cell continues to grow in size and ramps up production of proteins it will need during mitosis, including structural components of the mitotic spindle (the machinery that pulls chromosomes apart). Organelles also increase in number so each daughter cell will have enough to function independently.
Just as important, G2 is a critical window for DNA repair. Because the cell has just finished replicating billions of base pairs during S phase, errors are inevitable. G2 is the last convenient opportunity to fix them. The preferred repair method during this phase is called homologous recombination, which is considered the most precise way to fix double-strand DNA breaks. It works by using the freshly made sister copy of each chromosome as a template, essentially matching the damaged stretch against an identical backup. This repair method is only available in late S phase and G2, because the backup copy doesn’t exist before replication.
The G2/M Checkpoint
Before a cell can leave G2 and enter mitosis, it must pass a checkpoint. Think of it as a gate that stays closed until the cell proves its DNA is intact and fully replicated. If DNA damage is detected, sensor proteins trigger a signaling cascade that halts the cycle in G2, buying time for repairs.
The damage sensors work by activating two key signaling proteins (ATM and ATR) that detect different types of DNA problems. These sensors relay the alarm downstream, ultimately preventing the activation of the protein complex that drives a cell into mitosis. That complex, formed by cyclin B1 paired with a partner enzyme called CDK1, is the master switch for cell division. Throughout most of G2, this complex is kept inactive by inhibitory chemical tags placed on it by a protein called Wee1. Only when repairs are complete and conditions are right does a different set of enzymes strip those tags off, flipping the switch and launching mitosis.
The tumor suppressor p53 plays a specific and somewhat surprising role in this process. It isn’t required to initially stop the cell at the G2 checkpoint after DNA damage. Cells lacking p53 can still arrest at G2. But p53 is essential for sustaining that arrest. Without it, cells escape the checkpoint prematurely and enter mitosis before repairs are finished. In experiments, p53-deficient cells that slipped out of G2 arrest too early underwent extensive cell death because they tried to divide with damaged chromosomes.
How Cells Know They’re Big Enough
Beyond DNA quality, cells also appear to monitor their physical size before committing to division. Research in yeast has shown that a gradient of a polarity protein acts as a ruler, sensing cell length. When the cell reaches a threshold size, that signal feeds into the same molecular switch (the CDK1 complex) that triggers mitosis. While the details differ between yeast and human cells, the principle holds: G2 integrates information about both genome integrity and cell growth before giving the green light.
What Happens When the G2 Checkpoint Fails
When the G2 checkpoint doesn’t work properly, cells enter mitosis carrying unrepaired DNA. The consequences are serious. Damaged chromosomes can break apart or be distributed unevenly during division, leading to daughter cells with the wrong number of chromosomes. This condition, called chromosomal instability, is a hallmark of cancer.
Researchers have identified a specific signaling pathway involved in recovering from G2 checkpoint arrest that is frequently disrupted in tumors. Dysregulation of this pathway reduces DNA repair efficiency during G2 and directly increases chromosomal instability. The pattern shows up across many cancer types: it appears in roughly 20% of melanomas, 40% of ovarian cancers, and up to 60% of uterine cancers. Overexpression of one key protein in this pathway (Aurora kinase A) alone produces cells with abnormally variable chromosome numbers, a direct marker of genomic chaos.
This connection between G2 checkpoint failure and cancer isn’t just academic. Because many cancers already have defective G1 checkpoints (often due to p53 mutations), they become heavily dependent on the G2 checkpoint to catch DNA errors. That dependency creates a vulnerability.
G2 Phase as a Target in Cancer Treatment
The reliance of certain cancers on the G2 checkpoint has opened a therapeutic strategy: deliberately disabling it. If a tumor cell already carries DNA damage and its only remaining safety net is the G2/M checkpoint, removing that net forces the cell into mitosis with catastrophic levels of damage, triggering cell death.
One approach targets Wee1, the protein that keeps the mitosis switch (CDK1) in the “off” position during G2. Inhibiting Wee1 pushes cells through the checkpoint before repairs are complete, causing significant DNA damage and cell death. In preclinical studies, combining a Wee1 inhibitor with immune checkpoint therapy (a type of immunotherapy) led to complete tumor rejection in all treated animals. The Wee1 inhibitor worked by stripping away the cancer cell’s ability to pause its cycle in response to damage caused by immune cells, making the immune attack far more lethal.
This strategy is especially promising for tumors with mutated p53, since those cells have already lost the ability to sustain G2 arrest on their own. Removing the Wee1 brake on top of that leaves the cancer cell with no way to stop and repair itself before division.